stockrow
Saturday 7 November 2026
Export ACET’s income statement to Excel — free account
Adicet Bio, Inc.
ACET Healthcare Biotechnology
Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.
- EPS
- +63.4%
- Free cash flow
- +24.9%
Quarter to June 2026, against a year earlier
3.05
0.13
+4.45%
Follow ACET
Alert me
Adicet Bio, Inc. (ACET) P/E ratio
Adicet Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACET Adicet Bio, Inc. | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| ABVC ABVC BioPharma, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| EDSA Edesa Biotech, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)